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The development left ventricular hypertrophy (LVH) rep-
resents a critical milestone in patients with hypertensive
heart disease (HHD). This structural remodeling and the
associated abnormalities in diastolic function portend an
increased risk of both mortal and morbid events (1–4).
Treatment that results in the regression of LVH is associ-
ated with a reduction in these event rates (5–8). However,
success in reversing LVH using existing pharmaceutical
regimens has neither been uniform nor complete, particu-
larly in patients with drug-resistant, refractory hypertension.
See page 901
Abnormalities in the autonomic nervous system appear to
contribute to the resistance both to treatment and to the
induction of structural remodeling (9,10). The role played
by autonomic imbalance in patients with HHD serves to
underscore the importance of the development of a series of
novel management strategies that target autonomic modu-
lation (Table 1). One such novel strategy is the use of renal
artery denervation (RAD) in refractory hypertension.
Renal Artery Denervation
RAD, produced by catheter-based production of a spiral
array of radiofrequency lesions in both renal arteries, has
been shown to reduce blood pressure (BP) in patients with
hypertension resistant to multiple drugs in 2 clinical trials
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trolled Hypertension] I and II) (11,12). A third trial in
patients with refractory hypertension, Symplicity III, has
begun enrolling patients. In this issue of the Journal, Brandt
et al. (13) report the results of an echocardiographic sub-
study from patients enrolled in Symplicity II. There were 2
key conclusions from this study: RAD treatment resulted in
the reduction of LV mass and an improvement in diastolic
function.
Effects on LV mass. RAD was associated with a decrease
in LV mass by 13% after just 1 month of treatment and 17%
after 6 months of treatment. These changes in LV mass
caused the incidence of LVH to fall from 63% at baseline to
33% 6 months after RAD; however, the average LV mass
for the patients treated with RAD did not reach normal,
and some patients did not have regression of LVH. By
contrast, LV mass tended to increase in the control group.
Of note, patients without LVH at baseline had no signifi-
cant decrease in LV mass, that is, atrophy did not occur.
Because a number of pharmaceutical-based clinical trials
have shown that the regression of LVH has led to an
improved prognosis (5–8), it is anticipated that LVH
regression induced by RAD will also be associated with a
reduction in mortal and morbid events; however, to date, this
remains an unproven hypothesis.
Effects on diastolic function. RAD was associated with an
improvement in LV diastolic function as measured by
Doppler indices of LV lengthening (increased mitral annu-
lar E=) and by reduction of left atrial dimension. By contrast,
these measures of diastolic function became more abnormal
in the control group. Taken together, these changes suggest
that there was a decrease in left atrial and LV diastolic
pressures. This effect is further substantiated by a 39%
reduction in N-terminal pro–B-type natriuretic peptide,
compared with only an 8% reduction in the control group.
RAD mechanisms of action. How does RAD cause the
regression of LVH and the improvement in diastolic func-
tion? It seems likely that both a decrease in LV myocardial
load and a decrease in activation of the sympathetic nervous
system contribute to these outcomes for the following
reasons. First, the decrease in LV mass 1 month after RAD
was faster and larger than any previous study in which a
pressure-overload state (hypertension or aortic stenosis) was
removed. Second, even in the 6 RAD-treated patients that
did not have a decrease in BP, there was a significant
decrease in LV mass. Third, the extent to which RAD
caused LV mass regression after 6 months was larger than
might have been predicted based on previous pharmacolog-
ical studies. For example, on average, drug treatment results
in a 10% decrease in LV mass, whereas RAD caused a 17%
decrease despite comparable decreases in BP (14% and 15%,
respectively) (5–8).
It also seems likely that RAD caused the dramatic
improvement in LV diastolic function through interdepen-
dent mechanisms that include the regression of LVH,
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Autonomic modulation strategies: future strategies and
applications. Abnormalities in autonomic regulation with
veractivation of the sympathetic nervous system (SNS) and
enin-angiotensin-aldosterone system (RAAS) and reduced
agal tone contribute to the development and progression of
oth HHD and heart failure (HF) (9,10). Although current
pharmacological treatment may block individual components
of the sympathetic nervous system and RAAS overactivation,
RAD may provide a more integrated approach to normalizing
autonomic activity. By altering both afferent and efferent renal
nerve signaling, RAD appears to decrease afferent sympathetic
signals from the kidney to the brain, reducing systemic sym-
pathetic activation, and to decrease efferent sympathetic signals
from the brain to the kidneys, reducing vasoconstriction and
RAAS activation (9,10).
In addition to RAD, other novel strategies to modulate the
autonomic nervous system are being developed for the treat-
ment of HHD and HF (Table 1). These include stimulation of
the carotid baroreceptor, vagal nerve, and spine cord using
implanted stimulators. Each of these technologies will have
specific advantages and disadvantages, but all seem likely to
have the potential for benefit in at least some patients with
Autonomic Modulation Studies (Ongoing or ComTable 1 Autonomic Modulation Studies (Ong
Trial Name Disease
Spinal cord stimulation
Defeat HF HFrEF
SCS Heart HFrEF
Baroreceptor activation therapy
DEBuT-HT HTN
DEBuT-HET HTN
Rheos Feasibility Trial HTN
Rheos Pivotal Trial HTN
HOPE 4 HF HFpEF
XR-1 BAT HTN
XR-1 HF HFrEF
Vagal nerve stimulation
CardioFit HFrEF
INOVATE-HF HFrEF
NECTAR-HF HFrEF
ACES II HFpEF
Renal artery denervation
SWAN HT HTN
SWAN HF HFr&pEF
ARSENAL HTN
SYMPLICITY HTN I, II, III HTN
SYMPLICITY HF HFrEF
ACES II Acute Carotid Sinus Endovascular Stimulation II Study; Arsena
Patients; CardioFit  CardioFitTM for Treatment of Heart Failure; DEBuT-H
Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic
heart failure with a reduced ejection fraction; HOPE 4HFHealth Outcom
Inovate-HF  Increase of Vagal Tone in CHF; Nectar-HF  Neural Card
Hypertension Therapy System; SCS Heart Spinal Cord Stimulation For H
Failure; SWAN-HT  Renal Sympathetic Modification in Patients With E
Uncontrolled Hypertension; SymplicityHF  Renal Denervation in Patien
Barostim Neo System in the Treatment of Resistant Hypertension; XR-1HHD.Data are sufficient to suggest potential strengths and poten-
tial limitations with individual strategies. For example, RAD
can be accomplished with a single invasive procedure that does
not require ongoing treatment to cause autonomic modulation.
The effects on BP are profound and sustained. Its success does
not require patient compliance. By contrast, RAD cannot be
done in the presence of renal artery stenosis, specific renal
artery anatomy (2 or more renal arteries/kidney). RAD is not
titratable, and cannot be terminated or reversed. Thus far, as
indicated by data in the Symplicity II trial echocardiographic
substudy, there have been no issues with persistent hypotension
or myocardial atrophy (13). Whether renal artery reinnervation
will eventually occur is not known.
Who should receive autonomic modulation treatment? Cur-
rent data suggest that patients across the spectrum of HHD
may represent reasonable target populations. These HHD
patients include those with refractory hypertension, those with
hypertensive LVH, and those with hypertension-induced HF.
Even patients with hypertension that is not refractory to drug
treatment may be future candidates. In these HHD patients,
autonomic modulation could reduce cost of treatment and
improve patient compliance. All HHD patients with HF,
regardless of the ejection fraction (EF), may benefit. Caution
should probably be applied to patients with HF and a reduced
d)or Completed)
Sponsor ID #
Medtronic NCT01112579
ST. Jude NCT01362725
CVRx NCT00710190
CVRx NCT00710294
CVRx NCT01077180
CVRx NCT00442286
CVRx NCT00957073
CVRx NCT01471834
CVRx NCT01471860
Biocontrol NCT00461019
Biocontrol NCT01303718
Boston Scientific NCT01385176
Medtronic NCT01458483
Biosense Webster NCT01417221
Biosense Webster NCT01402726
St. Jude NCT01438229
Medtronic NCT01418261
Medtronic NCT01392196
ty and Efficacy Study of Renal Artery Ablation in Resistant Hypertension
vice Based Therapy in Hypertension Trial; Defeat-HF  Determining the
ilure; HFpEF heart failure with a preserved ejection fraction; HFrEF
pective Evaluation for Heart FailureWith EF 40%; HTN hypertension;
rapy for Heart Failure Study; Rheos Pivotal Trial  Rheos™ Baroreflex
ilure; SWAN-HF Renal Sympathetic Modification in Patients With Heart
l Hypertension; Symplicity HTN-3  Renal Denervation in Patients With
Chronic Heart Failure & Renal Impairment Clinical Trial; XR-1 BAT 
rostim Neo System in the Treatment of Heart Failure.pleteoing
l Safe
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HF and a preserved EF; for this group of HF patients, there is
no current guideline-based treatment to reduce morbidity and
mortality.
Conclusions
RAD caused regression of LVH and improvement in
diastolic function; the mechanisms responsible for these
effects include both reduced LV load and the change in
autonomic modulation itself. This and other autonomic
modulation strategies hold enormous promise for the treat-
ment of patients with hypertensive heart disease.
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